VistaGen Therapeutics, Inc. (VTGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
VTGN Stock Summary
- VISTAGEN THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.93% of US listed stocks.
- As for revenue growth, note that VTGN's revenue has grown -112.65% over the past 12 months; that beats the revenue growth of just 0.51% of US companies in our set.
- In terms of volatility of its share price, VTGN is more volatile than 98.5% of stocks we're observing.
- Stocks that are quantitatively similar to VTGN, based on their financial statements, market capitalization, and price volatility, are MEIP, SYBX, TCRX, PIRS, and OGEN.
- VTGN's SEC filings can be seen here. And to visit VISTAGEN THERAPEUTICS INC's official web site, go to www.vistagen.com.
VTGN Valuation Summary
- VTGN's price/sales ratio is -254.8; this is 5096.08% lower than that of the median Healthcare stock.
- VTGN's EV/EBIT ratio has moved down 0 over the prior 82 months.
Below are key valuation metrics over time for VTGN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
VTGN | 2023-01-30 | -254.8 | 1.6 | -0.7 | -0.2 |
VTGN | 2023-01-27 | -235.5 | 1.5 | -0.7 | -0.2 |
VTGN | 2023-01-26 | -213.4 | 1.3 | -0.6 | -0.1 |
VTGN | 2023-01-25 | -197.8 | 1.2 | -0.6 | -0.1 |
VTGN | 2023-01-24 | -201.1 | 1.3 | -0.6 | -0.1 |
VTGN | 2023-01-23 | -198.9 | 1.2 | -0.6 | -0.1 |
VTGN Growth Metrics
- The 5 year cash and equivalents growth rate now stands at -53.61%.
- Its year over year price growth rate is now at -61.19%.
- Its 2 year price growth rate is now at 94.39%.

The table below shows VTGN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | -0.1856 | -59.9431 | -64.6911 |
2022-06-30 | 1.0649 | -55.0519 | -60.3775 |
2022-03-31 | 1.1089 | -45.2565 | -48.7075 |
2021-12-31 | 1.5119 | -34.9499 | -61.579 |
2021-09-30 | 1.4676 | -27.893 | -56.4881 |
2021-06-30 | 1.4436 | -15.4397 | -46.9635 |
VTGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VTGN has a Quality Grade of C, ranking ahead of 36.05% of graded US stocks.
- VTGN's asset turnover comes in at 0.017 -- ranking 376th of 682 Pharmaceutical Products stocks.
- SAGE, SVRA, and EDIT are the stocks whose asset turnover ratios are most correlated with VTGN.
The table below shows VTGN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.017 | 1 | -4.522 |
2021-03-31 | 0.018 | 1 | -3.130 |
2020-12-31 | 0.018 | 1 | -2.501 |
2020-09-30 | 0.036 | 1 | -2.651 |
2020-06-30 | 0.000 | NA | -3.134 |
2020-03-31 | 0.000 | NA | -3.789 |
VTGN Price Target
For more insight on analysts targets of VTGN, see our VTGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $7.00 | Average Broker Recommendation | 1.12 (Strong Buy) |
VTGN Stock Price Chart Interactive Chart >
VTGN Price/Volume Stats
Current price | $0.25 | 52-week high | $1.79 |
Prev. close | $0.30 | 52-week low | $0.08 |
Day low | $0.25 | Volume | 12,901,843 |
Day high | $0.34 | Avg. volume | 7,486,061 |
50-day MA | $0.15 | Dividend yield | N/A |
200-day MA | $0.44 | Market Cap | 51.61M |
VistaGen Therapeutics, Inc. (VTGN) Company Bio
VistaGen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops products for patients with diseases and disorders involving the central nervous system. VistaGen Therapeutics serves customers in the United States.
Latest VTGN News From Around the Web
Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.
Alluring stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 11.11%), Pinterest, Inc. (NYSE:PINS -5.57%)VTGN has seen its SMA50 which is now 104.73%. In looking the SMA 200 we see that the stock has seen a -34.01%. PINS has seen its SMA50 which is … The post Alluring stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 11.11%), Pinterest, Inc. (NYSE:PINS -5.57%) appeared first on Stocks Equity . |
Morning Investor’s Alert: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 7.22%), LogicMark, Inc. (NASDAQ:LGMK 0.54%)VTGN has seen its SMA50 which is now 97.56%. In looking the SMA 200 we see that the stock has seen a -36.32%. LGMK has seen its SMA50 which is … The post Morning Investor’s Alert: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 7.22%), LogicMark, Inc. (NASDAQ:LGMK 0.54%) appeared first on Stocks Equity . |
Vistagen Announces Closing of Pherin Pharmaceuticals AcquisitionSOUTH SAN FRANCISCO, Calif., February 02, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin). Vistagen now owns all intellectual property ri |
Enrapturing stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 8.02%), Ault Alliance, Inc. (AMEX:AULT -1.43%)VTGN has seen its SMA50 which is now 65.33%. In looking the SMA 200 we see that the stock has seen a -52.40%. AULT has seen its SMA50 which is … The post Enrapturing stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 8.02%), Ault Alliance, Inc. (AMEX:AULT -1.43%) appeared first on Stocks Equity . |
Indicators from Technical Perspective: VistaGen Therapeutics, Inc. (NASDAQ:VTGN -2.78%), Muscle Maker, Inc. (NASDAQ:GRIL 0.42%)VTGN has seen its SMA50 which is now 48.79%. In looking the SMA 200 we see that the stock has seen a -57.16%. GRIL has seen its SMA50 which is … The post Indicators from Technical Perspective: VistaGen Therapeutics, Inc. (NASDAQ:VTGN -2.78%), Muscle Maker, Inc. (NASDAQ:GRIL 0.42%) appeared first on Stocks Equity . |
VTGN Price Returns
1-mo | 53.75% |
3-mo | 107.30% |
6-mo | 46.28% |
1-year | -83.33% |
3-year | -66.00% |
5-year | -78.99% |
YTD | 142.72% |
2022 | -94.72% |
2021 | 0.52% |
2020 | 181.28% |
2019 | -54.02% |
2018 | 35.14% |
Loading social stream, please wait...